U.S. markets closed

Theriva Biologics, Inc. (TOVX)

NYSE American - NYSE American Delayed Price. Currency in USD
0.4495+0.0095 (+2.16%)
At close: 04:00PM EDT
0.4500 +0.00 (+0.11%)
After hours: 07:54PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close0.4400
Bid0.4400 x 1200
Ask0.4600 x 1000
Day's Range0.4300 - 0.4600
52 Week Range0.2000 - 1.2000
Avg. Volume99,043
Market Cap7.708M
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
EPS (TTM)-1.1400
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for TOVX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Theriva Biologics, Inc.
    IRWD: Lowering target price to $8.00IRONWOOD PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • GlobeNewswire

    Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

    ROCKVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced the presentation of preclinical data demonstrating the potential synergy between lead product candidate, VCN-01 and liposomal irinotecan in a human pancreatic mouse xenograft. Data will be featured in a poster presentation at the American Society for Cell

  • Insider Monkey

    Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript

    Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript March 25, 2024 Theriva Biologics, Inc. beats earnings expectations. Reported EPS is $-0.34, expectations were $-0.41. Theriva Biologics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]

  • Thomson Reuters StreetEvents

    Q4 2023 Theriva Biologics Inc Earnings Call

    Q4 2023 Theriva Biologics Inc Earnings Call